Kyowa Kirin International
在场
Kyowa Kirin International 的所有者是 Kirin.
是其中之一......
Kirin 是一家在股票代码 2503 (JP) 下上市的公司。
Kirin 在 3 个国家有直接业务。Kirin 拥有 6家子公司，其中包括 Coca-Cola Beverages Northeast、Kyowa Chemical Industry 和 Kyowa Hakko Kirin。
他们在：
涉及Kirin的并购和融资。
- Kyowa Kirin International has announced the acquisition of Orchard Therapeutics (公布2024一月25号).
- Kyowa Kirin International has announced the acquisition of Orchard Therapeutics (公布2023十月6号).
高管
查看带有其 21 名主要高管的组织结构图
Kyowa Kirin International 搜索最多的简介
- Abdul Mullick, President
- Paula Soteropoulos, Director
- Wayne Bowler, Senior Vice President, Business Development & Allian...
创建提醒
跟踪 Kyowa Kirin International 的高管变动
药店
Kirin 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
Kyowa Kirin International 的最新新闻稿
- Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
- Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day | Orchard Therapeutics
- CTCL Global Care Collaborative Pioneers Consensus for Improving Diagnosis and Care in Cutaneous T-Cell Lymphoma (CTCL)
- Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. | Orchard Therapeutics
- Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome | Orchard Therapeutics
- IR Releases | Investors | Kyowa Kirin Co., Ltd.
- Kyowa Kirin Received Partial Change Approval of LUMICEF® for Palmoplantar Pustulosis in Japan - Kyowa Kirin
- Kyowa Kirin Received Approval for Calcimimetics Agent ORKEDIA® TABLETS 4mg in Japan - Kyowa Kirin
- Kyowa Kirin Received Partial Change Approval of Antineoplastic Mitomycin C Agent in Japan - Kyowa Kirin
- Kyowa Kirin Announces Phase III Study Results of bardoxolone methyl (RTA 402) in Japan and Discontinuation of Development - Kyowa Kirin
- View more press releases Close
通过电子邮件
